The challenge they faced:
As artificial intelligence became a critical component of drug discovery and development, this global biopharmaceutical company needed to understand how to scale and support its growing capabilities. Teams across regions used different tools, workflows, and data environments, making it difficult to collaborate and unlock the full potential of AI-driven science.
Our approach:
The assumption was that expert AI developers needed expert tools, while less technical users needed no-code environments. Our research across the global organization revealed something different: many AI experts also valued no-code tools because they enabled collaboration with business teams and non-technical colleagues. This insight unlocked a broader rollout strategy—no-code wasn't just for beginners, it was a collaboration layer that could scale across the entire organization. Platform consolidation reduced software expenses by 35% while expanding who could participate in AI-driven work.
The business impact:
- 35% projected reduction in software expenses through platform consolidation
- Quantified the benefits of a new collaboration platform connecting AI engineers and business users
- Clear roadmap for scaling AI capabilities and accelerating insight generation across global research teams
